From clinical trials to real-world evidence: Tofacitinib in the treatment of rheumatoid arthritis

20 Nov 2020
From clinical trials to real-world evidence:
Tofacitinib in the treatment of rheumatoid arthritis
Janus kinase inhibitors (JAKIs) have emerged as an effective class of therapy for rheumatoid arthritis (RA).1 At the EULAR virtual symposium, a group of specialists discussed recent updates on tofacitinib (Xeljanz®, Pfizer) – the first-in-class JAKI for the treatment of RA.

Related MIMS Drugs

Editor's Recommendations